Regulatory T cells (Tregs) suppress immune responses by conventional T cells (Tconv). This property can be used to mitigate unwanted and excessive immune responses through infusion of Tregs. On the other hand, Tregs also prevent the immune system from controlling cancer, which necessitates strategies to inhibit Tregs. Like Tconv, Tregs have an antigen receptor on their surface. This receptor must be activated to mobilize the function of each of these cell types.
We have however found that the transmission of signals by this receptor is different between Tregs and Tconv. Here, we will investigate whether these signaling differences can be exploited to selectively inhibit Tregs without simultaneous inhibition of Tconv. Moreover, we will investigate whether signaling via these antigen receptors can be altered to make Tregs more potent suppressors for inhibition of autoimmune disease and transplant rejection.